B-cell acute lymphoblastic leukemia · 3 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Vincristine and Prednisone Variant #01 | — | R 183 | 5d | — | — | ~1 | ~R 183 indirect | — |
Prednisone monotherapy Variant #11 Partial | — | R 138 | 7d | ~2.2 mo | ~14.1 mo | ~1 | ~R 138 PFS proxy · indirect | 8 |
Prednisone monotherapy Variant #11 Partial | BCR::ABL1 | R 138 | 7d | ~2.2 mo | ~14.1 mo | ~1 | ~R 138 PFS proxy · indirect | 8 |
3 of 3 regimens shown